Plain-English translation of NCT07401641 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After oral cancer surgery involving tissue reconstruction, controlling pain is crucial for healing. This trial compares two different intravenous pain-relief combinations: one using Dezocine plus Sufentanil, and the other using Nalbuphine plus Sufentanil. Researchers want to see which medication combination provides better pain control, fewer side effects, and better healing of the reconstructed tissue.
Pain after major oral cancer surgery can interfere with recovery and the survival of the reconstructed tissue. This study aims to find the most effective pain management approach to help patients heal better and experience fewer unwanted side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive one of the two pain-relief medication combinations through an intravenous pump that you can control yourself after surgery. You'll press a button when you need pain relief, and the pump will deliver a dose with built-in safety limits. The research team will check your pain levels, healing progress, and any side effects at 2, 24, and 48 hours after surgery, and monitor your tissue graft for the first week.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China